Gilead Sciences, Inc.
NEWS
Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
Gilead Sciences announced that its selonsertib to treat compensated cirrhosis from nonalcoholic steatohepatitis (NASH) did not meet its primary endpoint in the STELLAR-4 Phase III trial. Given Gilead’s expertise in liver diseases, the setback is particularly discouraging.
Gilead Sciences reported earnings per share profits for the fourth quarter of $1.44 per share, below analysts’ expectations of $1.70.
IDEA Pharma recently published its “Pharmaceutical Innovation Index 2018.” This report ranks biopharma companies on their ability to bring products from Phase I/II to market and then successfully commercialize them. They used a variety of sources, including company websites, third-party institutions such as clinicaltrials.gov, and syndicated and analyst reports to make their list.
The funds raised will be used to advance the company’s lead product into Phase II clinical trials, expand its Phase I pipeline, and scale-up its manufacturing capacity.
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
Although that is good news, cancer is the second-most common cause of death in the U.S., with more than 1.7 million new cancer cases each year and more than 600,000 cancer deaths. The report notes that one of the biggest factors in decreased cancer rates are lower tobacco smoking rates.
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
JOBS
IN THE PRESS